Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.57 Consensus Target Price from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.38.

YMAB has been the topic of several recent research reports. BMO Capital Markets decreased their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald initiated coverage on shares of Y-mAbs Therapeutics in a research report on Friday. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, August 12th.

Insider Buying and Selling

In related news, insider Thomas Gad sold 7,351 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total value of $95,563.00. Following the completion of the transaction, the insider now owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the sale, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. In the last 90 days, insiders sold 74,444 shares of company stock valued at $903,925. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its stake in shares of Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 17.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after purchasing an additional 52,610 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Y-mAbs Therapeutics by 8.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Up 2.0 %

NASDAQ YMAB opened at $12.49 on Tuesday. Y-mAbs Therapeutics has a 12 month low of $4.69 and a 12 month high of $20.90. The company’s 50 day simple moving average is $11.85 and its 200 day simple moving average is $13.72.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the prior year, the business earned ($0.14) EPS. As a group, analysts predict that Y-mAbs Therapeutics will post -0.55 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.